Randomized phase 3 efficacy and safety trial of proposed pegfilgrastim biosimilar MYL-1401H in the prophylactic treatment of chemotherapy-induced neutropenia
Abstract: Pegfilgrastim is indicated for reducing the duration of neutropenia and incidence of febrile neutropenia in patients receiving cytotoxic chemotherapy. Here, safety and efficacy of MYL-1401H, a proposed pegfilgrastim biosimilar, were investigated as prophylaxis for chemotherapy-induced neutropenia. This was a phase 3, multicenter, randomized, double-blind, parallel-group equivalence trial of MYL-1401H vs European Union–sourced reference pegfilgrastim. Patients with newly diagnosed stage II/III breast cancer eligible to receive (neo) adjuvant chemotherapy with docetaxel/doxorubicin/cyclophosphamide every 3 weeks for 6 cycles were enrolled and randomized 2:1 to 6 mg of MYL-1401H or reference pegfilgrastim 24 h (+ 2-h window after the first 24 h) after the end of chemotherapy. The primary efficacy endpoint was the duration of severe neutropenia in cycle 1 (i.e., days with absolute neutrophil count (ANC) < 0.5 × 109/L). Mean (standard deviation (SD)) duration of severe neutropenia in MYL-1401H and reference pegfilgrastim groups was 1.2 days (0.93) and 1.2 days (1.10), respectively. The 95% CI for least squares mean difference (− 0.285, 0.298) was within the predefined equivalence range of ± 1 day. Secondary endpoints, including grade ≥ 3 neutropenia (frequency, 91% and 82% for MYL-1401H and reference pegfilgrastim, respectively), time to ANC nadir (mean (SD), 6.2 (0.98) and 6.3 (1.57) days), and duration of post-nadir recovery (mean (SD), 1.9 (0.85) and 1.7 (0.91) days) were comparable. Overall safety profiles of the study drugs were comparable. MYL-1401H demonstrated equivalent efficacy and similar safety to reference pegfilgrastim and may be an equivalent option for reducing incidence of neutropenia
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
issn: 1432-0584
- Classification
-
Medizin, Gesundheit
- Keyword
-
Neutropenie
- Event
-
Veröffentlichung
- (where)
-
Freiburg
- (who)
-
Universität
- (when)
-
2019
- Creator
-
Waller, Cornelius
Ranganna, Gopinath M.
Pennella, Eduardo J.
Blakeley, Christopher
Hernandez-Bronchud, Miguel
Mattano, Leonard A.
Berzoy, Oleksandr
Voitko, Nataliia
Shparyk, Yaroslav
Lytvyn, Iryna
Rusyn, Andriy
Popov, Vasil
Láng, István
Beckmann, Katrin
Sharma, Rajiv
Baczkowski, Mark
Kothekar, Mudgal
Barve, Abhijit
- DOI
-
10.1007/s00277-019-03639-5
- URN
-
urn:nbn:de:bsz:25-freidok-1495256
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:52 AM CEST
Data provider
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Waller, Cornelius
- Ranganna, Gopinath M.
- Pennella, Eduardo J.
- Blakeley, Christopher
- Hernandez-Bronchud, Miguel
- Mattano, Leonard A.
- Berzoy, Oleksandr
- Voitko, Nataliia
- Shparyk, Yaroslav
- Lytvyn, Iryna
- Rusyn, Andriy
- Popov, Vasil
- Láng, István
- Beckmann, Katrin
- Sharma, Rajiv
- Baczkowski, Mark
- Kothekar, Mudgal
- Barve, Abhijit
- Universität
Time of origin
- 2019